Valeant Pharmaceuticals North America LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$59.7M
Doctors Paid
70,828
Transactions
205,576
2017 Total
$59.7M
Payment Breakdown by Category
Royalty/License$20.4M (34.3%)
Research$16.0M (26.8%)
Food & Beverage$5.0M (8.4%)
Consulting$3.8M (6.3%)
Travel$2.5M (4.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $20.4M | 51 | 34.3% |
| Unspecified | $16.0M | 3,281 | 26.8% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $5.5M | 1,760 | 9.3% |
| Food and Beverage | $5.0M | 190,070 | 8.4% |
| Consulting Fee | $3.8M | 1,347 | 6.3% |
| Charitable Contribution | $3.6M | 94 | 6.0% |
| Travel and Lodging | $2.5M | 8,049 | 4.2% |
| Grant | $1.8M | 54 | 3.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $941,228 | 286 | 1.6% |
| Gift | $97,582 | 132 | 0.2% |
| Education | $9,287 | 452 | 0.0% |
Payments by Type
General
$43.7M
202,295 transactions
Research
$16.0M
3,281 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2 ARM, PARALLEL GROUP STUDY COMPARING THE SAFETY AND EFFICACY OF IDP-123 LOTION AND IDP-123 VEHICLE LOTION IN THE TREATMENT OF ACNE VULGARIS | $4.5M | 0 | 546 |
| A Phase 3, Multi-Center, Double-Masked, Vehicle-Controlled, Randomized, Parallel-Group Study to Assess Loteprednol Etabonate Ophthalmic Gel, 0.38 BID and TID versus Vehicle Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery | $1.7M | 9 | 158 |
| Clinical Study of Approved Contact Lenses | $567,859 | 12 | 73 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris | $551,595 | 54 | 104 |
| A Multicenter, Open Label, Single-Arm Study evaluating the Safety and Pharmacokinetics of Efinaconazole 10 Topical Solution in Subjects with Mild to Severe Onychomycosis of the Toenails | $524,084 | 12 | 49 |
| IIS 2017-2753 Margolis | $400,000 | 1 | 1 |
| A Prospective Post Approval Study to Evaluate the Trulign Toric Posterior Chamber Intraocular Lens IOL | $399,432 | 4 | 192 |
| Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Instillations of Loteprednol Etabonate Ophthalmic Gel, 0.38, in Normal Healthy Volunteers | $356,600 | 1 | 5 |
| 2017-2784 Lebwohl | $350,000 | 1 | 1 |
| A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, VEHICLE CONTROLLED CLINICAL STUDY TO ASSESS THE SAFETY AND EFFICACY OF IDP-122 IN THE TREATMENT OF PLAQUE PSORIASIS | $330,543 | 0 | 86 |
| IISInman-George | $276,444 | 1 | 2 |
| A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, MULTIREGIONAL, ONE YEAR STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ORAL RIFAXIMIN DELAYED RELEASE TABLETS FOR INDUCTION OF CLINICAL REMISSION WITH ENDOSCOPIC RESPONSE AT 16 WEEKS FOLLOWED BY CLINICAL AND ENDOSCOPIC REMISSION AT 52 WEEKS IN SUBJECTS WITH ACTIVE MODERATE CROHNS DISEASE | $275,371 | 0 | 243 |
| A STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF ESCALATING DOSES OF SAN-300 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS. | $262,724 | 0 | 11 |
| A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, MULTIREGIONAL, ONE YEAR STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ORAL RIFAXIMIN DELAYED RELEASE TABLETS FOR INDUCTION OF CLINICAL REMISSION WITH ENDOSCOPIC RESPONSE AT 16 WEEKS FOLLOWED BY CLINICAL AND ENDOSCOPIC REMISSION AT 52 WEEKS IN SUBJECTS WITH ACTIVE MODERATE CROHN'S DISEASE | $258,226 | 2 | 239 |
| 2014-25 Palefsky AMC | $253,389 | 1 | 1 |
| 2014-26 Shofler | $252,041 | 1 | 2 |
| A REGISTRY OF SIPULEUCEL-T THERAPY IN MEN WITH ADVANCED PROSTATE CANCER | $238,018 | 1 | 269 |
| IIS 2015-1060-Markowitz | $206,215 | 1 | 2 |
| A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer PREDICT | $170,189 | 1 | 83 |
| IIS CheeverFong | $148,435 | 1 | 1 |
| A Prospective Multicenter, Randomized, Active-Controlled, Masked Clinical Study to Evaluate the Safety and Effectiveness of the enVista One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens in Subjects Undergoing Cataract Extraction. | $138,238 | 0 | 18 |
| IIS InmanGeorge | $138,222 | 1 | 1 |
| IIS Antonarakis | $129,275 | 1 | 1 |
| 2015-6 Birnbaum | $128,022 | 1 | 1 |
| 2015-6 Birbaum | $128,022 | 1 | 1 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | $126,132 | 25 | 46 |
| IIS McNeel | $119,719 | 1 | 1 |
| A PROSPECTIVE, SINGLE ARM, MULTICENTER, OBSERVATIONAL ASSESSMENT OF THE LONG TERM SAFETY AND EFFICACY OF SOLESTA INJECTABLE BULKING AGENT FOR THE TREATMENT OF FECAL INCONTINENCE SOFI | $119,262 | 2 | 632 |
| A PHASE 3, MULTICENTER, OPEN LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY OF IDP-118 LOTION IN THE TREATMENT OF PLAQUE PSORIASIS | $113,292 | 0 | 55 |
| A Study to Document the Safety and Effectiveness of a New Ophthalmic Viscosurgical Device OVD When Compared to a Control OVD | $106,659 | 1 | 14 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2017 |
|---|---|---|---|---|
| Richard Lindstrom, M.d, M.D | Ophthalmology | Bloomington, MN | $521,650 | $0 |
| Brant Inman, M.d, M.D | Urology | Durham, NC | $414,665 | $0 |
| Dr. Orit Markowitz | Dermatology | New York, NY | $409,480 | $0 |
| David Margolis, Md, MD | Dermatology | Philadelphia, PA | $400,024 | $0 |
| Unknown Provider | — | — | $378,673 | $0 |
| Dr. Mark Lebwohl | Dermatology | New York, NY | $350,643 | $0 |
| Mark Packer, M.d, M.D | Ophthalmology | Boulder, CO | $339,927 | $0 |
| Dr. Joel Palefsky, Md, MD | Internal Medicine | San Francisco, CA | $326,201 | $0 |
| Boni Elewski | Dermatology | Birmingham, AL | $257,876 | $0 |
| Rebecca Birnbaum | Psychiatry | New York, NY | $256,043 | $0 |
| Javier Alonso-Llamazares, M.d.phd, M.D.PHD | Dermatology | Coral Gables, FL | $252,235 | $0 |
| Howard Loff, Md, MD | Ophthalmology | Atlantic Beach, FL | $250,000 | $0 |
| Dr. Mark Pimentel, M.d, M.D | Gastroenterology | Los Angeles, CA | $240,939 | $0 |
| Lynette Johns, O.d, O.D | Corneal and Contact Management | Waltham, MA | $227,686 | $0 |
| Dr. Robert Osher, Md, MD | Ophthalmology | Cincinnati, OH | $205,000 | $0 |
| Timothy Page, M.d, M.D | Ophthalmology | Birmingham, MI | $186,754 | $0 |
| Leon Kircik, Md, MD | Dermatology | Lousiville, KY | $178,288 | $0 |
| Dr. George Martin, Md, MD | Dermatology | Kihei, HI | $175,302 | $0 |
| Dr. Aaron Lech, O.d, O.D | Optometrist | Roseville, CA | $174,591 | $0 |
| Dr. Maria Surprenant, D.p.m, D.P.M | Foot Surgery | South Miami, FL | $150,170 | $0 |
| Unknown Provider | — | — | $148,435 | $0 |
| James Peace, M.d. Inc, M.D. INC | Retina Specialist | Inglewood, CA | $144,001 | $0 |
| Dr. Cathleen Mccabe, M.d, M.D | Ophthalmology | Bradenton, FL | $143,215 | $0 |
| Dr. Naum Shaparin, M.d, M.D | Pain Medicine | Bronx, NY | $143,044 | $0 |
| Dr. Amy Wechsler, M.d, M.D | Dermatology | New York, NY | $138,393 | $0 |
Ad
Top Products
- XIFAXAN $22.0M
- LOTEMAX GEL $2.9M
Associated Products (35)
- JUBLIA $3.6M
- LOTEMAX GEL $3.5M
- BESIVANCE $1.0M
- RIFAXIMIN $809,231
- OCUCOAT $790,851
- JUBLIA EFINACONAZOLE $686,781
- AKREOS AO $674,856
- APRISO $669,399
- ZYLET $627,117
- SIPULEUCEL-T $588,020
- ADDYI $585,304
- ALREX $553,137
- RELISTOR ORAL $364,431
- BEPREVE $354,428
- ZYCLARA $346,933
- ISTALOL $336,798
- H2CH4BREATH $260,989
- IDP-118 $237,486
- SJO $136,477
- LOTEMAX SUSPENSION $121,914
- IBSCHEK $101,999
- UCERIS TABLETS $90,415
- MACUGEN $84,414
- VITESSE $78,643
- EFUDEX-GENERIC $72,812
- MULTI-FOCAL LENS $67,629
- WELLBUTRIN XL $63,050
- ZIRGAN $62,554
- AMVISC $52,741
- LUZU LULICONAZOLE $49,019
- NITROPRESS $34,200
- TIMOPTIC-XE 0.50 $33,311
- SOLODYN $26,906
- LOTEMAX OINTMENT $26,592
- LATANOPROSTENE BUNOD $19,728
Payment Categories
- Food & Beverage $5.0M
- Consulting $3.8M
- Travel & Lodging $2.5M
- Research $16.0M
- Royalties $20.4M
About Valeant Pharmaceuticals North America LLC
Valeant Pharmaceuticals North America LLC has made $59.7M in payments to 70,828 healthcare providers, recorded across 205,576 transactions in the CMS Open Payments database. In 2017, the company paid $59.7M. The top product by payment volume is XIFAXAN ($22.0M).
Payments were distributed across 236 medical specialties. The top specialty by payment amount is Optometrist ($5.8M to 12,416 doctors).
Payment categories include: Food & Beverage ($5.0M), Consulting ($3.8M), Research ($16.0M), Travel & Lodging ($2.5M), Royalties ($20.4M).
Valeant Pharmaceuticals North America LLC is associated with 35 products in the CMS Open Payments database, including JUBLIA, LOTEMAX GEL, and BESIVANCE.